Dyadic Announces Analyst Coverage Initiated by Zacks Small-Cap Research
October 16 2018 - 8:30AM
JUPITER, Fla., Oct. 16, 2018 (GLOBE NEWSWIRE) --
Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global
biotechnology company focused on further improving and applying its
proprietary C1 gene expression platform to speed up the development
and lower the cost of biologic vaccines and drugs at flexible
commercial scales, today announced that Zacks Small-Cap Research
(“Zacks SCR”) has initiated analyst coverage of Dyadic. Information
regarding analyst coverage is available on our website.
The information above and on our website is
solely for informational purposes, and is not intended as a
solicitation to make investments. Please note that any opinions,
estimates or forecasts regarding Dyadic's performance made by
analysts are theirs alone and do not represent opinions, forecasts
or predictions of Dyadic or its management. Dyadic does not by its
reference above or on the website, or by distribution, imply its
endorsement of or concurrence with such information, conclusions or
recommendations.
Zacks SCR has received compensation from Dyadic
directly for providing non-investment banking services to Dyadic
for a period of no less than one year and expects to receive
quarterly payments totaling a maximum fee of $30,000 annually for
such non-investment banking services provided to Dyadic. The
non-investment banking services provided to Dyadic includes the
preparation of analyst reports, investor relations services,
investment software, financial database analysis, organization of
non-deal road shows, and attendance fees for conferences sponsored
or co-sponsored by Zacks SCR.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila, named C1.
The C1 microorganism, which enables the development and large scale
manufacture of low cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, lower production costs and improve the
performance of biologic vaccines and drugs at flexible commercial
scales. Dyadic is using the C1 technology and other technologies to
conduct research, development and commercial activities for the
development and manufacturing of human and animal vaccines (such as
virus like particles (VLPs) and antigens), monoclonal antibodies,
Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or
biobetters, and other therapeutic proteins. Dyadic pursues research
and development collaborations, licensing arrangements and other
commercial opportunities with its partners and collaborators to
leverage the value and benefits of these technologies in
development and manufacture of biopharmaceuticals. In particular,
as the aging population grows in developed and undeveloped
countries, Dyadic believes the C1 technology may help bring
biologic drugs to market faster, in greater volumes, at lower cost,
and with new properties to drug developers and manufacturers and,
hopefully, improve access and cost to patients and the healthcare
system, but most importantly save lives.
Please visit Dyadic’s website at
http://www.dyadic.com for additional information, including details
regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements are based on management’s
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements involve risks, uncertainties and other factors that
could cause Dyadic’s actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements and are cautioned not
to place undue reliance on such forward-looking statements. Dyadic
expressly disclaims any intent or obligation to update or revise
any forward-looking statements to reflect actual results, any
changes in expectations or any change in events. Factors that could
cause results to differ materially include, but are not limited to:
(1) general economic, political and market conditions; (2) our
ability to generate the required productivity, stability, purity,
performance, cost, safety and other data necessary to carry out and
implement our biopharmaceutical research and business plans and
strategic initiatives; (3) our ability to retain and attract
employees, consultants, directors and advisors; (4) our ability to
implement and successfully carry out Dyadic’s and third parties
research and development efforts; (5) our ability to obtain new
license and research agreements; (6) our ability to maintain our
existing access to, and/or expand access to third party contract
research organizations in order to carry out our research projects
for ourselves and third parties; (7) competitive pressures and
reliance on key customers and collaborators; (8) the pharmaceutical
and biotech industry, governmental regulatory and other agencies'
willingness to adopt, utilize and approve the use of the C1 gene
expression platform; and (9) other factors discussed in Dyadic’s
publicly available filings, including information set forth under
the caption “Risk Factors” in our December 31, 2017 Annual
Report filed with the OTC Markets on March 27, 2018, and our
March 31, 2018 Quarterly Report filed with the OTC Markets on May
10, 2018. New risks and uncertainties arise from time to time, and
it is impossible for us to predict these events or how they may
affect us.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Accounting Officer
Phone: (561) 743-8333
Email: prawson@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024